CompletedPhase 3

Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol

Egypt60 participantsStarted 2013-03

Plain-language summary

We aim to compare carbetocin with misoprostol for the prevention of postpartum hemorrhage in patients with severe preeclampsia. The primary outcome is postpartum haemorrhage (blood loss of ≥ 500 ml) while our Secondary outcomes include use of additional uterotonics, need for blood transfusion, maternal adverse drug reaction, maternal complications and maternal death

Who can participate

Age range19 Years – 42 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Persistent cerebral or visual disturbances or cerebral edema.
✓. Persistent epigastric pain with nausea or vomiting, or both.
✓. Systolic ≥160 mmHg or diastolic ≥110 mmHg on 2 occasions at least 6 h apart with the patient at bed rest.
✓. Proteinuria of ≥5 g on 24-hour urine collection. Urine dipsticks are not accurate for this purpose.
✓. Oliguria (˂500 mL in 24 hours).
✓. Pulmonary edema.
✓. Thrombocytopenia.

What they're measuring

Prevention of postpartum hemorrhage in patients with severe preeclampsia using carbetocin versus misoprostol

Timeframe: 24 hours after delivery

Trial details

NCT IDNCT02086994

Sponsorkhalid abd aziz mohamed

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-08

View on ClinicalTrials.gov More Severe Pre-eclampsia, Postpartum Condition or Complication trials